Biotest has great expertise in the area of therapy with polyvalent immunoglobulins (IVIg) in primary immune deficiencies and autoimmune diseases. Building on this expertise we develop drugs for the treatment of chronic progressive diseases of the immune system.
The projects involve new and further developments in the IVIg area. We are also adding the two monoclonal antibodies Tregalizumab (BT-061) and BT-063 to the existing portfolio of biological medications in immunology. They are being developed in rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus) and for the treatment of other autoimmune diseases.
Biotest has been active for many years in the development and production of hyperimmunoglobulins. These are medications that are used in the treatment of chronic viral infectious diseases such as hepatitis B to prevent reinfection after organ transplantation. A recent Biotest development in this area is Civacir®, a hepatitis C hyperimmunoglobulin for the prevention of reinfection of a hepatitis C virus-induced liver transplant.